Annalise.ai vs Rayscape (2026)

AI Health Index verifiedAugust 4, 2026
Verdict

Two comprehensive chest radiograph platforms, both claiming to read for a very large number of findings, and the comparison should not be run on that number. Annalise is the more established, operating as a joint venture with a large radiology provider and carrying regulatory footprints across multiple markets. Rayscape is smaller and has the more interesting evidence: independent evaluation in a tuberculosis screening setting, which is a harder test than a reader study because the deployment is exactly where radiologist capacity is thinnest and the consequence of a miss is highest. It also adds longitudinal comparison across prior scans and offers on premise deployment. For a hospital standardising across sites, Annalise carries fewer unknowns. For a screening programme, Rayscape has been tested in something resembling the real conditions.

The case for Annalise.ai
  • The evidence includes independent evaluation in a tuberculosis screening context, which is a harder and more consequential test than a retrospective reader study.
  • Findings breadth on chest radiography is substantial and the platform adds longitudinal comparison across a patient's prior scans, so change over time is visible rather than each study read in isolation.
  • Both on premise and cloud integration are offered, which matters where images cannot leave the institution or the country.
The case for Rayscape
  • The comprehensive chest radiograph position is established across a large findings set with regulatory footprints in multiple markets, backed by a joint venture with a large radiology provider that supplies real reading volume.
  • Deployment maturity is greater, which matters for a modality where the failure mode is a subtle finding missed at scale rather than a dramatic error.
  • For a health system standardising chest radiograph AI across sites, the more widely deployed platform carries fewer unknowns.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Annalise.ai and Rayscape are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact Annalise.ai Rayscape
Primary category Radiology & Imaging AI Radiology & Imaging AI
Founded 2019 2019
Headquarters Sydney, Australia Timisoara, Romania
Website annalise.ai rayscape.ai
Attribute Matrix

Side by Side

Axis
A
Annalise.ai
R
Rayscape
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each record in one paragraph

Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.

Annalise.ai

The AI Health Index awards Annalise.ai its top capability grade on AI Centrality, FDA and Regulatory Status and Setting and Specialty Coverage. Set against Rayscape, Annalise.ai grades higher on FDA and Regulatory Status and Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

Rayscape

The AI Health Index awards Rayscape its top capability grade on AI Centrality. Set against Annalise.ai, Rayscape grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

FAQ

Questions buyers ask

Should we choose Annalise.ai or Rayscape?

On the axes where the AI Health Index separates them, Annalise.ai grades higher on FDA and Regulatory Status and Setting and Specialty Coverage, and Rayscape grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Rayscape leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.

Where do Annalise.ai and Rayscape differ most?

The widest separation the AI Health Index records between Annalise.ai and Rayscape is on FDA and Regulatory Status, where Annalise.ai grades A and Rayscape grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.

Where do Annalise.ai and Rayscape grade the same?

The AI Health Index grades Annalise.ai and Rayscape the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

Disclosure

Comprehensive chest radiograph products claim large numbers of findings and those numbers are not comparable across vendors, because each counts differently and the per finding performance varies enormously within any such list. Ask both for performance on the specific findings that matter in your population rather than for the headline count. Neither vendor publishes a security attestation or trust centre.

Prevalence is the other uncontrolled variable: a model validated in a high tuberculosis burden setting will produce very different positive predictive values in a low prevalence one, and neither vendor publishes performance stratified that way.